GlobeNewswire Inc.··NaAlumis' Psoriasis Drug Shows Strong Phase 3 Results, Paving Way for 2026 FDA Filing
Alumis reports positive Phase 3 results for envudeucitinib, achieving 68% PASI 90 skin clearance in plaque psoriasis patients, with FDA filing planned for late 2026.
ALMSquality of lifeTYK2 inhibitor